CYAD-N2T-005 (DEPLETHINK) (R/R)

CYAD-N2T-005 (DEPLETHINK) (R/R)

An Open-label, Phase I Study to Assess the Safety of NKR-2 Treatment Administration After a Non-myeloablative Preconditioning Chemotherapy in Relapse/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Patients.


Study Treatments


Inclusion criteria


Exclusion criteria


Participating sites

Link